A share price of Nautilus Biotechnology Inc [NAUT] is currently trading at $0.79, up 10.50%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NAUT shares have gain 13.25% over the last week, with a monthly amount glided 8.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nautilus Biotechnology Inc [NASDAQ: NAUT] stock has seen the most recent analyst activity on December 05, 2024, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $1.75 for it. Previously, Guggenheim started tracking the stock with Buy rating on June 27, 2024, and set its price target to $6. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $8 on January 06, 2022. Cowen initiated its recommendation with a Outperform. Goldman started tracking with a Neutral rating for this stock on August 04, 2021, and assigned it a price target of $10. In a note dated July 13, 2021, Jefferies initiated an Buy rating and provided a target price of $13 on this stock.
Nautilus Biotechnology Inc experienced fluctuations in its stock price throughout the past year between $0.66 and $3.09. Currently, Wall Street analysts expect the stock to reach $2.5 within the next 12 months. Nautilus Biotechnology Inc [NASDAQ: NAUT] shares were valued at $0.79 at the most recent close of the market. An investor can expect a potential return of 216.46% based on the average NAUT price forecast.
Analyzing the NAUT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.32 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7234 points at the first support level, and at 0.6535 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8399, and for the 2nd resistance point, it is at 0.8865.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nautilus Biotechnology Inc [NASDAQ:NAUT] is 17.36. Further, the Quick Ratio stands at 17.36, while the Cash Ratio is 4.08.
Transactions by insiders
Recent insider trading involved Mowry Anna, CFO and Treasurer, that happened on May 29 ’25 when 15000.0 shares were purchased. Chief Scientist, Mallick Parag completed a deal on May 08 ’25 to buy 12000.0 shares. Meanwhile, Chief Scientist Mallick Parag bought 1500.0 shares on May 12 ’25.
